Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rogier Versteeg

Showing results (81-90 of 139) with videos related to

Pageof 14
Sort By:
Cancer Research|February 19, 2009
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapyJohannes H Schulte, Soyoung Lim, Alexander Schramm, et al.
Journal of Neuropathology and Experimental Neurology|February 8, 2006
OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomasTalitha de Haas, Esmeralda Oussoren, Wieslawa Grajkowska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastomaJanine Stutterheim, Annemieke Gerritsen, Lily Zappeij-Kannegieter, et al.
Plos One|December 16, 2014
CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patientsAli Rihani, Bram De Wilde, Fjoralba Zeka, et al.
Oncotarget|April 9, 2016
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionLaurel T Bate-Eya, Ilona J M den Hartog, Ida van der Ploeg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2013
Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumoursLaurel T Bate-Eya, Marli E Ebus, Jan Koster, et al.
Pediatric Blood & Cancer|January 7, 2014
Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastomaAli Rihani, Tom Van Maerken, Bram De Wilde, et al.
The Journal of Molecular Diagnostics : JMD|December 3, 2014
Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastomaEsther M van Wezel, Danny Zwijnenburg, Lily Zappeij-Kannegieter, et al.
Journal of the National Cancer Institute|May 1, 2015
The role of histone demethylase KDM4B in Myc signaling in neuroblastomaJun Yang, Alaa M AlTahan, Dongli Hu, et al.
European Journal of Pediatrics|December 18, 2008
Prevalence of congenital heart defects in neuroblastoma patients: a cohort study and systematic review of literatureKlaartje van Engelen, Johannes H M Merks, Jan Lam, et al.
Pageof 14

Showing results (81-90 of 139) with videos related to

Sort By:
Pageof 14
Cancer Research|February 19, 2009
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapyJohannes H Schulte, Soyoung Lim, Alexander Schramm, et al.
Journal of Neuropathology and Experimental Neurology|February 8, 2006
OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomasTalitha de Haas, Esmeralda Oussoren, Wieslawa Grajkowska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastomaJanine Stutterheim, Annemieke Gerritsen, Lily Zappeij-Kannegieter, et al.
Plos One|December 16, 2014
CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patientsAli Rihani, Bram De Wilde, Fjoralba Zeka, et al.
Oncotarget|April 9, 2016
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionLaurel T Bate-Eya, Ilona J M den Hartog, Ida van der Ploeg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2013
Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumoursLaurel T Bate-Eya, Marli E Ebus, Jan Koster, et al.
Pediatric Blood & Cancer|January 7, 2014
Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastomaAli Rihani, Tom Van Maerken, Bram De Wilde, et al.
The Journal of Molecular Diagnostics : JMD|December 3, 2014
Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastomaEsther M van Wezel, Danny Zwijnenburg, Lily Zappeij-Kannegieter, et al.
Journal of the National Cancer Institute|May 1, 2015
The role of histone demethylase KDM4B in Myc signaling in neuroblastomaJun Yang, Alaa M AlTahan, Dongli Hu, et al.
European Journal of Pediatrics|December 18, 2008
Prevalence of congenital heart defects in neuroblastoma patients: a cohort study and systematic review of literatureKlaartje van Engelen, Johannes H M Merks, Jan Lam, et al.
Pageof 14